Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for ALYFTREK ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended ...

Discover how Vertex Pharmaceuticals achieved 12% Q2 2025 revenue growth with new launches like ALYFTREK, CASGEVY, & JOURNAVX.

NICE has approved a once-daily cystic fibrosis drug, as NHS England secures wider access for patients.

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.

ALYFTREK is approved in the U.S., UK, and Canada for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation ...

I think that's the case with Vertex. Here are seven reasons why Vertex is a no-brainer stock to buy on the dip.

ALYFTREK brings a potentially transformative therapy to up to 60 people living with CF in Canada who were not previously eligible for a CFTR modulator. As the first once-daily CFTR modulator, ALYFTREK ...

Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic ...

Vertex’s Alyftrek is a CFTR modulator that works by correcting the malfunctioning protein made by the CFTR gene, helping patients live more independently and reducing the time they need to spend in ...